Effects of β2-agonists on airway tone and bronchial responsiveness

Journal of Allergy and Clinical Immunology

Volumn 110, Issue 6 SUPPL., 2002, Pages

  Larj, Michael J ^a   Bleecker, Eugene R ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Asthma; Combination therapy; Corticosteroid; Pharmacogenetics; Tachyphylaxis; 2 agonist

Indexed keywords

BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CORTICOSTEROID; SALBUTAMOL; SALMETEROL; BETA 2 ADRENERGIC RECEPTOR; BRONCHODILATING AGENT;

AIRWAY; ASTHMA; BETA ADRENERGIC STIMULATION; BRONCHODILATATION; BRONCHOSPASM; BRONCHUS REACTIVITY; CONFERENCE PAPER; DRUG EFFECT; EXERCISE INDUCED ASTHMA; FORCED EXPIRATORY VOLUME; GENOTYPE; HUMAN; LUNG FUNCTION; PHARMACOGENETICS; PRIORITY JOURNAL; TACHYPHYLAXIS; BRONCHUS HYPERREACTIVITY; DRUG POTENTIATION; REVIEW; SMOOTH MUSCLE;

ADRENERGIC BETA-AGONISTS; ASTHMA; BRONCHIAL HYPERREACTIVITY; BRONCHOCONSTRICTION; BRONCHODILATOR AGENTS; HUMANS; MUSCLE, SMOOTH; RECEPTORS, ADRENERGIC, BETA-2;

EID: 0036917649     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1067/mai.2002.130045     Document Type: Conference Paper

References (38)

1. National Institutes of Health. National Heart, Lung, and Blood Institute. National Asthma Education and Prevention Program. Guidelines for the Diagnosis and Management of Asthma Expert Panel Report 2. Publication No. 97-4051. 1997. [Pamphlet]
2. Drazen JM, Israel E, Boushey HA, et al, for the National, Heart, Lung, and Blood Institute's Asthma Clinical Research Network. Comparison of regularly scheduled with as-needed use of albuterol in mild asthma. N Engl J Med 1996;335:841-7.
3. Greening AP, Ind PW, Northfield M, et al, on behalf of Allen and Hanburys Limited UK Study Group. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Lancet 1994;344:219-24.
4. Woolcock A, Lundback B, Ringdal N, et al. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med 1996;153:1481-8.
5. Bleecker ER, Tinkelman DG, Ramsdell J, et al. Proventil HFA provides bronchodilation comparable to ventolin over 12 weeks of regular use in asthmatics. Chest 1998;113:283-9.
6. Tinkelman DG, Bleecker ER, Ramsdell J, et al. Proventil HFA and ventolin have similar safety profiles during regular use. Chest 1998;113:290-6.
7. van Essen-Zandvliet EE, Hughes MD, Waalkens HJ, et al, and the Dutch Chronic Non-specific Lung Disease Study Group. Effects of 22 months of treatment with inhaled corticosteroids and/or beta-2-agonists on lung function, airway responsiveness, and symptoms in children with asthma. Am Rev Respir Dis 1992;146:547-54.
8. Pearlman DS, Chervinsky P, LaForce C, et al. A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma. N Engl J Med 1992;327:1420-5.
9. Lundback B, Rawlinson DW, Palmer JBD, on behalf of a European Study Group. Twelve month comparison of salmeterol and salbutamol as dry powder formulations in asthmatic patients. Thorax 1993;48:148-53.
10. Nelson HS, Berkowitz RB, Tinkelman DA, et al. Lack of subsensitivity to albuterol after treatment with salmeterol in patients with asthma. Am J Respir Crit Care Med 1999;159:1556-61.
11. Palmqvist M, Persson G, Lazer L, et al. Inhaled dry-powder formoterol and salmeterol in asthmatic patients: Onset of action, duration of effect and potency. Eur Respir J 1997;10:2484-9.
12. Palmqvist M, Ibsen T, Mellén A, et al. Comparison of the relative efficacy of formoterol and salmeterol in asthmatic patients. Am J Respir Crit Care Med 1999;160:244-9.
13. O'Byrne PM, Barnes PJ, Rodriguez-Roisin R, et al. Low dose inhaled budesonide and formoterol in mild persistent asthma: The OPTIMA randomized trial. Am J Respir Crit Care Med 2001;164:1392-7.
14. Vathenen AS, Knox AJ, Higgins BG, et al. Rebound increase in bronchial responsiveness after treatment with inhaled terbutaline. Lancet 1988;1:554-8.
15. van Schayck CP, Graafsma SJ, Visch MB, et al. Increased bronchial hyperresponsiveness after inhaling salbutamol during 1 year is not caused by subsensitization to salbutamol. J Allergy Clin Immunol 1990;86:793-800.
16. Wong CS, Wahedna I, Pavord ID, et al. Effect of regular terbutaline and budesonide on bronchial reactivity to allergen challenge. Am J Respir Crit Care Med 1994;150:1268-73.
17. Kraan J, Koëter GH, vd Mark ThW, et al. Changes in bronchial hyperreactivity induced by 4 weeks of treatment with antiasthmatic drugs in patients with allergic asthma: A comparison between budesonide and terbutaline. J Allergy Clin Immunol 1985;76:628-36.
18. Cockcroft DW, O'Byrne PM, Swystun VA, et al. Regular use of inhaled albuterol and the allergen-induced late asthmatic response. J Allergy Clin Immunol 1995;96:44-9.
19. 2-adrenoceptor agonist, salmeterol, on airway hyperresponsiveness in patients with mild asthma. N Engl J Med 1992;327:1198-203.
20. 2-agonists in asthma. N Engl J Med 1992;327:1204-8.
21. Cockcroft DW, McParland CP, Britto SA, et al. Regular inhaled salbutamol and airway responsiveness to allergen. Lancet 1993;342:833-7.
22. McFadden ER Jr, Gilbert IA. Exercise-induced asthma. N Engl J Med 1994;330:1362-7.
23. Kemp JP, Dockhorn RJ, Busse WW, et al. Prolonged effect of inhaled salmeterol against exercise-induced bronchospasm. Am J Respir Crit Care Med 1994;150:1612-5.
24. Nelson JA, Strauss L, Skowronski M, et al. Effect of long-term salmeterol treatment on exercise-induced asthma. N Engl J Med 1998;339:141-6.
25. Bhagat R, Kalra S, Swystun VA, et al. Rapid onset of tolerance to the bronchoprotective effect of salmeterol. Chest 1995;108:1235-9.
26. Rosenthal RR, Busse WW, Kemp JP, et al. Effect of long-term salmeterol therapy compared with as-needed albuterol use on airway hyperresponsiveness. Chest 1999;116:595-602.
27. 2 agonist salmeterol in mild to moderate asthmatic patients. Thorax 1993;48:1121-4.
28. 2-agonists in allergic asthmatic patients. Chest 2001;119:1306-15.
29. Marsh DG, Neely JD, Breazeale DR, et al. Linkage analysis of IL4 and other chromosome 5q31.1 markers and total serum immunoglobulin E concentrations. Science 1994;264:1152-6.
30. Meyers DA, Postma DS, Panhuysen CIM, et al. Evidence for a locus regulating total serum IgE levels mapping to chromosome 5. Genomics 1994;23:464-70.
31. Postma DS, Bleecker ER, Amelung PJ, et al. Genetic susceptibility to asthma - Bronchial hyperresponsiveness coinherited with a major gene for atopy. N Engl J Med 1995;333:894-900.
32. Xu J, Postma DS, Howard TD, et al. Major genes regulating total serum immunoglobulin E levels in families with asthma. Am J Hum Genet 2000;67:1163-73.
33. Xu J, Meyers DA, Ober C, et al. Genomewide screen and identification of gene-gene interactions for asthma-susceptibility loci in three U.S. populations: Collaborative study on the genetics of asthma. Am J Hum Genet 2001;68:1437-46.
34. 2-adrenergic receptor. N Engl J Med 2002;346:536-8.
35. 2-adrenergic receptor and asthma. Am J Respir Crit Care Med 1997;156:S156-62.
36. 2-Adrenergic receptor Arg 16/Arg 16 genotype is associated with reduced lung function, but not with asthma, in the Hutterites. Am J Respir Crit Care Med 2000;162:599-602.
37. 2-adrenergic receptor on the response to regular use of albuterol in asthma. Am J Respir Crit Care Med 2000;162:75-80.
38. 2 adrenoceptor polymorphism. Thorax 2000;55:762-7.